Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

April 13, 2018: By Jon Swedien

Novartis has entered an agreement to acquire AveXis and its gene therapy platform for $8.7 billion.

AveXis’ lead drug candidate, AVXS-101, has the potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy. Novartis believes the acquisition can also help it advance its gene therapy capabilities more generally.

“We have a robust internal portfolio of gene therapies in ophthalmology and neuroscience in Novartis Institutes for Biomedical Research,” Novartis CEO Vas Narasimhan told Reuters. “And we look forward to using AveXis’ capabilities and technical development capabilities to be able to advance that portfolio.”

The boards of both companies each unanimously approved the transaction. Novartis agreed to pay $218 per share. The deal is expected to close in mid-2018, Novartis said.

This is Novartis’ second deal for a gene therapy this year. In February, Novartis struck a licensing deal to develop and commercialize Spark Therapeutics’ gene therapy, voretigene neparvovec, outside the US. That deal is potentially worth more than $170 million, according to Spark. Voretigene neparvovec is an FDA-approved treatment for retinal dystrophies caused by mutations in the RPE65 gene.

Novartis had cash on hand after selling its stake in a consumer health care joint venture with GlaxoSmithKline for $13 billion in March.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023